"I still haven't ruled out the possibility that the Covid trial or a Zenith event could result in significant success, in which case Don will be perceived as a hero by some, but it sure is not a good way to run a company."

Hummmm,,,really??,,,with no milestones acheived over years of plodding along in RVX,,,,,not knowing that covid viruses were part of a target market for apabetalone,,,university researchers had to tell Dr. Wong and all! Resembles throwing darts ata dart board,,and that is from day one of our research. I dont see anything remotely related to DMcC being a hero in the chair of CEO. In regards to Zenith we are almost 10 years in since the spin out of this science/technology and not one penny of true value has been produced for the shareholders who have been kept at arms length from control of those very shares they own. All the while having interest from several major pharmas which seem to be somewhat indifferent to the CEOs excitement. If we gain any value at all it will most likely be thru the hard work and invested dollars of a third party. Our team sits back in wait for a third party which is the major cause of our inactivity. Couple that with not knowing one iota about costs and timings around trial protocol or meeting any forward statements!! And having a noted 40 member team with an average salary of over $130,000.00 per annum. Dead money for many years out imo. Note we are working with one molecule!,,All these years and one gd molecule. No urgency in pushing a plan on the library in wait. Another carrot I assume. There are several business alternatives which would drive shareholder value but non are being taken. Its just down right pitiful!